Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early development

Abstract

The addendum of the ICH E9 guideline on the statistical principles for clinical trials introduced the estimand framework. The framework is designed to strengthen the dialog between different stakeholders, to introduce greater clarity in the clinical trial objectives and to provide alignment between the estimand and statistical analysis. Estimand framework related publications thus far have mainly focused on randomized clinical trials. The intention of the Early Development Estimand Nexus (EDEN), a task force of the cross‐industry Oncology Estimand Working Group (www.oncoestimand.org), is to apply it to single arms Phase 1b or Phase 2 trials designed to detect a treatment‐related efficacy signal, typically measured by objective response rate. Key recommendations regarding the estimand attributes include that in a single arm early clinical trial, the treatment attribute should start when the first dose is received by the participant. Focusing on the estimation of an absolute effect, the population‐level summary measure should reflect only the property used for the estimation. Another major component introduced in the ICH E9 addendum is the definition of intercurrent events and the associated possible ways to handle them. Different strategies reflect different clinical questions of interest that can be answered based on the journeys an individual subject can take during a trial. We provide detailed strategy recommendations for intercurrent events typically seen in early‐stage oncology. We highlight where implicit assumptions should be made transparent as whenever follow‐up is suspended, a while‐on‐treatment strategy is implied.

Duration of and time to response in oncology clinical trials from the perspective of the estimand framework

“…The model provides the conditional overall response rate (cORR) for every time point t after the index date. Another approach assessing the whole population is suggested by the EMA (2017) guidance 7 . It is defined as the time in response (Table 2, estimand 5): On patient level, DOR is defined as the time from onset of response to progression or death and is set to 0 for a patient with no response.…”